Takayuki Nakagawa1, Kouji Ohta2, Takako Naruse3, Miyuki Sakuma3, Syohei Fukada3, Nao Yamakado3, Misaki Akagi3, Kazuki Sasaki3, Chieko Niwata3, Shigehiro Ono3, Tomonao Aikawa3. 1. Department of Oral and Maxillofacial Surgery, Program of Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-Ward, Hiroshima, 734-8553, Japan. tnakaga@hiroshima-u.ac.jp. 2. Department of Public Oral Health, Program of Oral Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-Ward, Hiroshima, 734-8553, Japan. 3. Department of Oral and Maxillofacial Surgery, Program of Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-Ward, Hiroshima, 734-8553, Japan.
Abstract
PURPOSE: Integrin αvβ3 is an essential molecule for tumor angiogenesis. This study aimed to investigate the anti-tumor effect of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma (OSCC) through its inhibitory effect on angiogenesis. METHODS: In this study, we investigated the effect of MK-0429 on cellular function and angiogenesis in vitro with the use of an immortalized human umbilical vein endothelial cell, HUEhT-1, which is immortalized by the electroporatic transfection of hTERT. The effect of MK-0429 on the integrin αvβ3 signaling pathway was examined by FAK, MEK1/2 and ERK 1/2 phosphorylation. The anti-angiogenic effect of MK-0429 was evaluated by in vitro tube formation assay. The anti-tumor effect on OSCC was assessed by administrating MK-0429 to mouse oral cancer xenografts. RESULTS: MK-0429 inhibited cell proliferation, migration, and adhesion of HUEhT-1 in a dose-dependent manner. FAK, MEK and ERK phosphorylation were significantly blocked by MK-0429 treatment. Tube formation was suppressed by MK-0429 in dose-dependent manner. Tumor progression was significantly suppressed by MK-0429 administration in mouse oral cancer xenografts. Histological study revealed that MK-0429 decreased tumor vascularization. CONCLUSION: These results indicated integrin αvβ3 as a therapeutic target for OSCC and suggested that MK-0429 might be clinically applicable as an anti-tumor agent with potent anti-angiogenic activity.
PURPOSE: Integrin αvβ3 is an essential molecule for tumor angiogenesis. This study aimed to investigate the anti-tumor effect of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma (OSCC) through its inhibitory effect on angiogenesis. METHODS: In this study, we investigated the effect of MK-0429 on cellular function and angiogenesis in vitro with the use of an immortalized human umbilical vein endothelial cell, HUEhT-1, which is immortalized by the electroporatic transfection of hTERT. The effect of MK-0429 on the integrin αvβ3 signaling pathway was examined by FAK, MEK1/2 and ERK 1/2 phosphorylation. The anti-angiogenic effect of MK-0429 was evaluated by in vitro tube formation assay. The anti-tumor effect on OSCC was assessed by administrating MK-0429 to mouse oral cancer xenografts. RESULTS: MK-0429 inhibited cell proliferation, migration, and adhesion of HUEhT-1 in a dose-dependent manner. FAK, MEK and ERK phosphorylation were significantly blocked by MK-0429 treatment. Tube formation was suppressed by MK-0429 in dose-dependent manner. Tumor progression was significantly suppressed by MK-0429 administration in mouse oral cancer xenografts. Histological study revealed that MK-0429 decreased tumor vascularization. CONCLUSION: These results indicated integrin αvβ3 as a therapeutic target for OSCC and suggested that MK-0429 might be clinically applicable as an anti-tumor agent with potent anti-angiogenic activity.
Authors: K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum Journal: J Clin Invest Date: 2000-02 Impact factor: 14.808
Authors: Douglas G McNeel; Jens Eickhoff; Fred T Lee; David M King; Dona Alberti; James P Thomas; Andreas Friedl; Jill Kolesar; Rebecca Marnocha; Jennifer Volkman; Jianliang Zhang; Luz Hammershaimb; James A Zwiebel; George Wilding Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: Gunnar Wichmann; Susan Cedra; Daphne Schlegel; Marlen Kolb; Susanne Wiegand; Andreas Boehm; Mathias Hofer; Andreas Dietz Journal: Anticancer Res Date: 2017-02 Impact factor: 2.480
Authors: S Hariharan; D Gustafson; S Holden; D McConkey; D Davis; M Morrow; M Basche; L Gore; C Zang; C L O'Bryant; A Baron; D Gallemann; D Colevas; S G Eckhardt Journal: Ann Oncol Date: 2007-08 Impact factor: 32.976
Authors: Françoise Perron-Sierra; Dominique Saint Dizier; Marc Bertrand; Annie Genton; Gordon C Tucker; Patrick Casara Journal: Bioorg Med Chem Lett Date: 2002-11-18 Impact factor: 2.823
Authors: Peter Hersey; Jeffrey Sosman; Steven O'Day; Jon Richards; Agop Bedikian; Rene Gonzalez; William Sharfman; Robert Weber; Theodore Logan; Manuela Buzoianu; Luz Hammershaimb; John M Kirkwood Journal: Cancer Date: 2010-03-15 Impact factor: 6.860
Authors: S O'Day; A Pavlick; C Loquai; D Lawson; R Gutzmer; J Richards; D Schadendorf; J A Thompson; R Gonzalez; U Trefzer; P Mohr; C Ottensmeier; D Chao; B Zhong; C J de Boer; C Uhlar; D Marshall; M E Gore; Z Lang; W Hait; P Ho Journal: Br J Cancer Date: 2011-07-12 Impact factor: 7.640